Trade Legend Biotech Corporation - LEGN CFD

Add to favourite

39.61

1.93%

0.14

Low: 39.37

High: 39.88

Market Trading Hours* (UTC) Opens on Monday at 14:30

Mon - Fri: 14:30 - 21:00

Summary
Historical Data

Trading сonditions

Spread

0.14

Long position overnight fee

-0.023512%

Short position overnight fee

0.00129%

Overnight fee time

22:00 (UTC)

Min traded quantity

Currency

USD

Margin

50.00%

Stock exchange

United States of America

Commission on trade

Key Stats

Prev. Close	38.86
Open	39.58
1-Year Change	-36.95%
Day's Range	39.37 - 39.88

Last Week
Last Month
Last Year
Last two Years
Max

Daily
Weekly
Monthly

Date	Close	Change	Change (%)	Open	High	Low
Feb 21, 2025	39.61	0.25	0.64%	39.36	39.93	39.35
Feb 20, 2025	38.86	0.08	0.21%	38.78	39.57	38.25
Feb 19, 2025	38.69	0.73	1.92%	37.96	39.11	37.96
Feb 18, 2025	38.17	1.26	3.41%	36.91	38.92	36.82
Sep 21, 2023	62.69	0.00	0.00%	62.69	63.95	62.40
Sep 20, 2023	64.22	0.14	0.22%	64.08	65.95	64.08
Sep 19, 2023	65.40	-0.53	-0.80%	65.93	67.19	64.90
Sep 18, 2023	66.73	2.82	4.41%	63.91	67.44	63.91
Sep 15, 2023	66.38	2.30	3.59%	64.08	66.55	64.08
Sep 14, 2023	65.10	0.42	0.65%	64.68	65.94	64.08
Sep 13, 2023	65.31	-0.20	-0.31%	65.51	66.95	64.68
Sep 12, 2023	66.62	-2.38	-3.45%	69.00	69.93	66.45
Sep 11, 2023	70.11	2.46	3.64%	67.65	70.40	67.65
Sep 8, 2023	67.63	1.97	3.00%	65.66	68.53	65.65
Sep 7, 2023	66.22	0.22	0.33%	66.00	67.68	66.00
Sep 6, 2023	67.15	-0.75	-1.10%	67.90	68.26	66.06
Sep 5, 2023	68.63	-2.87	-4.01%	71.50	71.50	67.72
Sep 1, 2023	71.58	2.58	3.74%	69.00	72.31	68.95
Aug 31, 2023	69.34	0.41	0.59%	68.93	69.98	68.50
Aug 30, 2023	69.53	1.09	1.59%	68.44	70.06	68.43

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission

Leverage

2:1

20
100
500
1000
10000

Investment

Trade size (Leverage x Investement):

Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Legend Biotech Corporation

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery and development of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM), as well as a comparison of the treatment with standard triplet therapy in revlimid-refractory multiple myeloma. The company also has a portfolio of earlier-stage autologous product candidates, which are in Phase I clinical trials for the treatment of gastric cancer and T cell lymphoma. In addition, it is developing CAR-T product candidates targeting CD20/CD22/CD19 for the treatment of non-hodgkins lymphoma, diffuse large B-cell lymphoma, and acute lymphoblastic leukemia. Further, the company has product candidates in early preclinical and clinical development for the treatment of solid tumors as well as infectious diseases. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. Legend Biotech Corporation was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.

News

Microsoft Stock Price Forecast for 2025 and beyond: Third party price target

We assess the likely level of the Microsoft stock price in 5 years, and possible drivers behind the stock’s past performance. Read on...

18:29, 7 February 2025

Ripple XRP price prediction: Third-party price target

Discover the ripple (XRP) price predictions for 2025 and beyond, with analyst price targets and CFDs trading strategies on Capital.com

15:29, 6 February 2025

Apple Store on Fifth Avenue, New York, October 2016

Apple (AAPL) stock price forecast: third-party price target

We looked at the forecasts for Apple stock in 10 years to see where the price would likely be at that point and the challenges the company could face. Read more.

11:22, 6 February 2025